Discontinuing Zepbound (Tirzepatide) for Eating Disorders
Tirzepatide should not be used for eating disorders and must be discontinued immediately, as it is not an evidence-based treatment and may worsen the underlying psychiatric condition. The American Psychiatric Association 2023 guidelines provide no support for GLP-1 receptor agonists in eating disorder management 1.
Critical Context: Inappropriate Use
Tirzepatide is FDA-approved only for type 2 diabetes and obesity—not eating disorders. Using it for eating disorders represents off-label use without supporting evidence and potentially contradicts established treatment principles 1.
Immediate Discontinuation Approach
Stop tirzepatide abruptly without tapering. Unlike medications requiring gradual dose reduction, GLP-1 receptor agonists do not cause physiological withdrawal syndromes that necessitate weaning 2. The medication can be discontinued at the current dose without titration.
Expected Physiological Changes After Stopping
- Weight regain occurs rapidly and predictably: Most patients regain 25-75% of lost weight within 12 months of discontinuation 2
- Metabolic parameters deteriorate progressively: Waist circumference increases by 5-15 cm, systolic blood pressure rises by 7-10 mmHg, and hemoglobin A1c increases by 0.15-0.35% depending on degree of weight regain 2
- Cardiometabolic improvements reverse: Non-HDL cholesterol and fasting insulin levels return toward baseline, with greater deterioration correlating with more weight regain 2
Monitoring After Discontinuation
Monitor the following parameters at 1,3,6, and 12 months post-discontinuation:
- Weight and vital signs (blood pressure, heart rate, orthostatic changes) 1
- Complete blood count and comprehensive metabolic panel including electrolytes, liver enzymes, and renal function 1, 3
- ECG if patient has restrictive eating patterns or purging behaviors 1
- Nutritional status: Vitamin D, iron/ferritin, calcium, thiamine, and B12, as GLP-1RA use predisposes to deficiencies that may persist 4
Evidence-Based Treatment Transition
Immediately initiate appropriate eating disorder-focused psychotherapy as the primary intervention 1:
For Binge-Eating Disorder
- Cognitive-behavioral therapy (CBT) or interpersonal therapy in individual or group format as first-line treatment 1
- Consider lisdexamfetamine or antidepressants only if psychotherapy fails or patient preference dictates, but these are adjunctive to—not replacements for—psychotherapy 1
For Bulimia Nervosa
- Eating disorder-focused CBT as primary treatment 1
- Add fluoxetine 60 mg daily either initially or if minimal response to psychotherapy by 6 weeks 1
For Anorexia Nervosa
- Eating disorder-focused psychotherapy addressing normalization of eating behaviors, weight restoration, and psychological aspects (fear of weight gain, body image disturbance) 1
- Family-based treatment for adolescents and emerging adults with involved caregivers 1
Multidisciplinary Care Requirements
Establish a coordinated multidisciplinary team incorporating medical, psychiatric, psychological, and nutritional expertise with a documented, comprehensive, culturally appropriate treatment plan 1. This is a strong recommendation from the APA guidelines.
Critical Pitfalls to Avoid
- Do not taper tirzepatide: There is no physiological rationale for gradual dose reduction 2
- Do not substitute another weight-loss medication: This perpetuates inappropriate pharmacotherapy for a psychiatric condition requiring behavioral intervention 1
- Do not delay psychotherapy initiation: Medication discontinuation and evidence-based psychotherapy should occur simultaneously, not sequentially 1
- Anticipate and counsel about weight regain: Patients will likely regain weight; frame this as expected and address psychological distress proactively through eating disorder-focused therapy 2
- Screen for micronutrient deficiencies: GLP-1RA use causes vitamin D, iron, calcium, thiamine, and B12 depletion that requires assessment and repletion 4